Teens may have come up with a new way to detect, treat Lyme disease using CRISPR gene editing

A team of students from Lambert High School used CRISPR-based synthetic biology to develop a novel diagnostic and potential treatment approach for Lyme disease, reportedly detecting infection as early as two days versus two weeks with existing tests. The project — which included software modeling and a kit-style detection concept — placed the team in the global iGEM high-school top 10 in Paris and won a best-software award, underscoring rising U.S. talent even as funding for U.S. high-school synthetic biology programs faces political headwinds and China dominates participation. While promising, the work remains at an early stage and would require extensive validation before commercial or clinical impact.

Analysis

Market structure: The immediate commercial winners are industrial lab-suppliers and instrument makers (Thermo Fisher TMO, Danaher DHR, Illumina ILMN) because democratizing CRISPR increases recurring consumables/reagent demand while one-off school programs won’t move therapy revenues. Small diagnostic pure‑plays without clinical IP or manufacturing scale are losers as early-stage academic demos raise interest but not immediate sales. Expect pricing power to remain with high-end instrument and reagent incumbents; commoditization will pressure margins for low-end assay providers over 1–3 years.

Risk assessment: Tail risks include tightened biosecurity/regulatory restrictions or federal funding cuts (e.g., education/NIH) that could remove upside — a 10–30% shock to small-cap genomics and edtech exposure is plausible within 3–12 months. Near-term (days–weeks) market impact is minimal; medium-term (3–12 months) depends on grant announcements and M&A; long-term (2–5 years) depends on clinical translation and IP protection. Hidden dependencies: access to GMP manufacturing, LNP delivery partners, and university IP licenses are gating factors.

Trade implications: Tactical capital should overweight tools/supplies and underweight speculative genomics ETFs. Concrete plays: 1–3% positions in TMO/DHR for 6–18 months; maintain a 0.5–1% high-risk options sleeve in platform CRISPR (CRSP/NTLA) via 9–15 month call spreads. Hedge small-cap biotech exposure with short-dated puts on XBI (3-month) sized 1–2%.

Contrarian angles: The market likely underprices durable demand for consumables (multi-year revenue tail) and overprices near-term consumer/PR hype around teen projects translating into therapeutics. Historical parallel: widespread PCR education/DIY interest preceded a decade of instrument/reagent growth — expect a delayed but real revenue cycle. Unintended consequence: increased scrutiny could spike volatility in small-cap names; size positions accordingly and prefer blue‑chip suppliers over single-product diagnostics.

Key Decisions for Investors

• Establish a 2–3% combined long position split equally between Thermo Fisher (TMO) and Danaher (DHR); target 12–30% upside over 6–18 months driven by sustained consumables/reagent demand, trim if either reports <5% organic growth on next quarterly release.
• Allocate 0.5–1.0% to speculative CRISPR platform exposure (choose CRSP or NTLA). Implement via a 9–15 month call spread to limit downside (e.g., buy Jan 2026 LEAP calls and sell a higher strike) and reassess on clinical/partnership announcements.
• Run a relative-value pair: long DHR (1.0% notional) vs short ARK Genomic Revolution ETF (ARKG) (0.75% notional) to capture quality-vs-speculation divergence; rebalance on quarterly flows or >10% divergence in performance.
• Purchase 3-month ATM put protection on XBI sized 1–2% of portfolio to hedge a regulatory or biosecurity shock that would disproportionately hit small-cap biotech and diagnostics; review 30–60 days around NIH appropriations and any congressional hearings.
• Monitor three specific catalysts over the next 30–180 days: (1) NIH/HHS/DOE funding allocation announcements (impact on education-to-research pipelines), (2) major iGEM/academic-to-industry licensing deals (validate commercial pathway), and (3) any FDA/OSTP regulatory guidance on gene editing in non‑clinical settings; increase or cut exposures only once one of these triggers occurs.